Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells

Cancer Science

Volumn 99, Issue 1, 2008, Pages 107-112

  Susumu, Seiya ^a   Nagata, Yasuhiro ^a   Ito, Shinichiro ^a   Matsuo, Mitsutoshi ^a   Valmori, Danila ^b   Yui, Katsuyuki ^a   Udono, Heiichiro ^c   Kanematsu, Takashi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPITOPE; HEAT SHOCK COGNATE PROTEIN 70 NY ESO 1 ANTIGEN FUSION PROTEIN; HLA A2 ANTIGEN; LACTACYSTIN; NY ESO 1 ANTIGEN; PARAFORMALDEHYDE; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DESIGN; DRUG EFFICACY; ESCHERICHIA COLI; GENE FUSION; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VACCINE PRODUCTION;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CROSS REACTIONS; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 36949020042     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00654.x     Document Type: Article

References (37)

1. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: Review, standardization, and commentary. Cancer Immun 2004; 4: 1.
2. Van Der Brüggen P, Zhang Y, Chaux P et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002; 188: 51-64.
3. Jäger E, Jäger D, Knuth A. Antigen-specific immunotherapy and cancer vaccines. Int J Cancer 2003; 106: 817-20.
4. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004; 10: 909-15.
5. Arnold D, Faath S, Rammensee H, Schild H. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med 1995; 182: 885-9.
6. Blachere NE, Li Z, Chandawarkar RY et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997; 186: 1315-22.
7. Ciupitu AM, Petersson M, O'Donnell CL et al. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J Exp Med 1998; 187: 685-91.
8. Heikema A, Agsteribbe E, Wilschut J, Huckriede A. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Immunol Lett 1997; 57: 69-74.
9. Moroi Y, Mayhew M, Trcka J et al. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci USA 2000; 97: 3485-90.
10. Udono H, Yamano T, Kawabata Y, Ueda M, Yui K. Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70. Int Immunol 2001; 13: 1233-42.
11. Udono H, Saito T, Ogawa M, Yui Y. Hsp-antigen fusion and their use for immunization. Methods 2004; 32: 21-4.
12. O'Doherty U, Steinman RM, Peng M et al. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. J Exp Med 1993; 178: 1067-76.
13. Jäger E, Chen YT, Drijfhout JW et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 265-70.
14. Gnjatic S, Nagata Y, Jäger E et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci USA 2000; 97: 10.917-22.
15. Stockert E, Jäger E, Chen YT et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187: 1349-54.
16. +T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 2000; 60: 4499-506.
17. Jäger E, Nagata Y, Gnjatic S et al. Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000; 97: 4760-5.
18. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997; 388: 782-7.
19. Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 1999; 189: 821-9.
20. Przepiorka D, Srivastava PK. Heat shock protein - peptide complexes as immunotherapy for human cancer. Mol Med Today 1998; 4: 478-84.
21. Fourie AM, Sambrook JF, Gething MJ. Common and divergent peptide binding specificities of hsp70 molecular chaperones. J Biol Chem 1994; 269: 30.470-8.
22. Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 1914-18.
23. + T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. Proc Natl Acad Sci USA 2003; 100: 8862-7.
24. Ohkuri T, Sato M, Abe H et al. Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population. Cancer Sci 2007; 98: 1092-8.
25. + cancers. Proc Natl Acad Sci USA 2000; 97: 12.198-203.
26. Srivastava PK, Udono H, Blachere NE, Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994; 39: 93-8.
27. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995; 269: 1585-8.
28. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-9.
29. Norbury CC, Hewlett LJ, Prescott AR, Shastri N, Watts C. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity 1995; 3: 783-91.
30. Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 1995; 267: 243-6.
31. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976; 143: 1283-8.
32. Nagata Y, Ono S, Matsuo M et al. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci USA 2002; 99: 10.629-34.
33. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in.vitro and in.vivo. J Exp Med 1996; 184: 465-72.
34. Binder RJ, Han DK, Srivastava PK. CD91: A receptor for heat shock protein gp96. Nat Immunol 2000; 1: 151-5.
35. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001; 14: 303-13.
36. Asea A, Rehli M, Kabingu E et al. Novel signal transduction pathway utilized by extracellular HSP70: Role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002; 277: 15.028-34.
37. Bausinger H, Lipsker D, Ziylan U et al. Endotoxin-free heat-shock protein 70 fails to induce APC activation. Eur J Immunol 2002; 32: 3708-13.